摘要
目的 :了解氨氯地平治疗轻、中度高血压有效性及不良反应 (安全性 )的差异。方法 :应用Meta分析对 2 6篇文献 2 8项研究氨氯地平与其他抗高血压药物治疗轻、中度高血压的有效性、安全性进行同质性检验及合并效应量的估计。结果 :(1)同质性检验 :有效性 ,χ2 =2 9.13,自由度为 2 7;安全性 ,χ2 =2 7.95 ,自由度为 2 4 ,两者P均大于 0 .0 5。 (2 )合并效应量的估计 :有效性 ,OR合并 =1.2 6 1,OR合并95 %可信区间为 1.0 18～ 1.5 6 2。OR合并 的检验 :χ2 =4 .5 1,P <0 .0 5 ;安全性 :OR合并 =1.0 13,OR合并95 %可信区间为 0 .80 1～ 1.2 82。OR合并 的检验 :χ2 =0 .0 13,P >0 .0 5。结论 :氨氯地平治疗轻、中度高血压的疗效总体上优于目前常用药物 ,且其安全性较高。
AIM: To explore the efficacy and safety between amlodipine in treatment of mild to moderate hypertension. METHODS: The efficacy and safety of amlodipine or other drugs in treatment of mild to moderate hypertension were analyzed by Mata analysis in homogeneity test and combined test in 25 investigations. RESULTS: Homogeneity test showed that the cited studies of efficacy and safety were homogeous with χ 2 e= 29.13 , χ 2 s= 27.95 , P> 0.05 , respectively; and in combined test, the combined OR e= 1.261 , OR s= 1.013 and its 95% confidence interval were in 1.018 - 1.562 and 0.801 - 1.282 , respectively. CONCLUSION: The efficacy of amlodipine is significantly superior to those of the medications used at present in treatment of mild to moderate hypertension, and its safety is reliable.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2005年第2期204-210,共7页
Chinese Journal of Clinical Pharmacology and Therapeutics
